 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...208209210211212213214215216217218...235236» |
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: METHEP-2: Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases (clinicaltrials.gov) - Apr 19, 2015
P2, N=256, Recruiting, Sponsor: UNICANCER
Trial primary completion date: Feb 2014 --> May 2016
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Metastases: PRODIGE 18: Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab (clinicaltrials.gov) - Apr 19, 2015
P2, N=132, Recruiting, Sponsor: UNICANCER
Trial primary completion date: Feb 2014 --> May 2016 Trial primary completion date: Dec 2013 --> Jun 2015
- EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Trial primary completion date, IO biomarker, Metastases: Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) - Apr 19, 2015
P1, N=30, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Trial primary completion date: Dec 2013 --> Jun 2015 Trial primary completion date: Feb 2015 --> Jul 2015
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus (clinicaltrials.gov) - Apr 19, 2015
P2/3, N=252, Recruiting, Sponsor: Centre Georges Francois Leclerc
Trial primary completion date: Feb 2015 --> Jul 2015 Trial primary completion date: Oct 2014 --> Oct 2016
- || Vectibix (panitumumab) / Amgen
Trial primary completion date: PLANET: Safety and Efficacy Study of FOLFOX4+Panitumumab vs.FOLFIRI+Panitumumab in Subjects WT KRAS Colorectal Cancer and Liver-only Metastases (clinicaltrials.gov) - Apr 19, 2015
P2, N=80, Active, not recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Trial primary completion date: Oct 2014 --> Oct 2016 Trial primary completion date: Aug 2014 --> Aug 2015
- || 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date: Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Apr 19, 2015
P2, N=120, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center.
Trial primary completion date: Aug 2014 --> Aug 2015 Trial primary completion date: Oct 2015 --> Oct 2016
- Mekinist (trametinib) / Novartis, BeiGene
Trial suspension, Surgery, Metastases: SWOG-S1310: Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 19, 2015
P2, N=89, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2015 --> Oct 2016 Recruiting --> Suspended
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Study of Vitamin D in Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 18, 2015
P2, N=120, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Suspended Trial primary completion date: Mar 2015 --> Apr 2016
- ||| Xpovio (selinexor) / Karyopharm
New P1 trial, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Apr 17, 2015
P1, N=51, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Enrollment open, Metastases: Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer (clinicaltrials.gov) - Apr 16, 2015
P4, N=36, Recruiting, Sponsor: University of Chicago
Trial primary completion date: Mar 2015 --> Apr 2016 Not yet recruiting --> Recruiting
- || vanucizumab (RG7221) / Roche, Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: McCAVE: A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 14, 2015
P2, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: May 2017 --> Nov 2017
- || prexasertib (ACR-368) / Acrivon Therap
Trial primary completion date, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Apr 14, 2015
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: May 2017 --> Nov 2017 Trial primary completion date: Oct 2017 --> Jun 2016
- ||| Biomarker, Trial initiation date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Apr 14, 2015
P2, N=610, Not yet recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2017 --> Jun 2016 Initiation date: Apr 2015 --> Jan 2015 | Trial primary completion date: May 2019 --> Nov 2020
- Avastin (bevacizumab) / Roche
Trial primary completion date, Metastases: Genistein in Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 14, 2015
P1/2, N=24, Recruiting, Sponsor: Randall F. Holcombe
Initiation date: Apr 2015 --> Jan 2015 | Trial primary completion date: May 2019 --> Nov 2020 Trial primary completion date: Apr 2015 --> May 2016
- |||| Avastin (bevacizumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors (clinicaltrials.gov) - Apr 14, 2015
P2/3, N=70, Active, not recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Apr 2015 --> May 2016 Trial primary completion date: Jun 2014 --> Jan 2012
- leucovorin calcium / Generic mfg.
Enrollment change: Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=12, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2014 --> Jan 2012 N=10 --> 12
- || Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial primary completion date: SARILNIUSATURN: Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (clinicaltrials.gov) - Apr 14, 2015
P2, N=57, Recruiting, Sponsor: Sanofi
N=10 --> 12 Trial primary completion date: Dec 2015 --> Jul 2015
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial primary completion date, Combination therapy, Metastases: Study of REOLYSIN (clinicaltrials.gov) - Apr 14, 2015
P1, N=20, Recruiting, Sponsor: Oncolytics Biotech
Trial primary completion date: Dec 2015 --> Jul 2015 Trial primary completion date: Jun 2015 --> Jun 2016
- || New P2/3 trial: DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer (clinicaltrials.gov) - Apr 14, 2015
P2/3, N=100, Not yet recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Surgery, Post-surgery: A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 14, 2015
P2, N=21, Active, not recruiting, Sponsor: NorthShore University HealthSystem
Trial primary completion date: Jun 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial primary completion date, Metastases: HCRN GI14-186: Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Apr 13, 2015
P2, N=30, Recruiting, Sponsor: Safi Shadha, M.D.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> Jun 2016
- ||||| foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma, Avastin (bevacizumab) / Roche
New P2 trial, Metastases: PRIMIER: Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 10, 2015
P2, N=100, Not yet recruiting, Sponsor: University of Southern California
- | New P2 trial, Metastases: Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients (clinicaltrials.gov) - Apr 10, 2015
P2, N=82, Recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- ipatasertib (RG7440) / Roche
Enrollment closed, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 3, 2015
P1, N=122, Active, not recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> Jun 2016 Recruiting --> Active, not recruiting
- |||| Fotivda (tivozanib) / Kyowa Kirin, LG Chem
Trial completion, Trial primary completion date, Combination therapy, Metastases: A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy (clinicaltrials.gov) - Apr 3, 2015
P2, N=265, Completed, Sponsor: Astellas Pharma Inc
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Sep 2013
- |||||||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P3 trial, New P4 trial: A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer (clinicaltrials.gov) - Apr 2, 2015
P3, N=700, Recruiting, Sponsor: Xu jianmin
- |||| simtuzumab (GS 6624) / Gilead
Trial completion, Metastases: Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma (clinicaltrials.gov) - Apr 2, 2015
P2, N=266, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | Trial primary completion date: Feb 2014 --> Sep 2013 Active, not recruiting --> Completed
- | HyperAcute Pancreas (algenpantucel-L) / Lumos Pharma
New P2 trial: Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Apr 1, 2015
P2, N=48, Not yet recruiting, Sponsor: NewLink Genetics Corporation
- | Erbitux (cetuximab) / Eli Lilly
New P2 trial, Metastases: TIME-PRODIGE 28: Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC) (clinicaltrials.gov) - Apr 1, 2015
P2, N=136, Recruiting, Sponsor: UNICANCER
- | Kinselby (resminostat) / 4SC, Yakult Honsha
Trial completion, Combination therapy, Metastases: SHORE: 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma (clinicaltrials.gov) - Apr 1, 2015
P1/2, N=17, Completed, Sponsor: 4SC AG
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Mar 31, 2015
P=N/A, N=42, Active, not recruiting, Sponsor: Philip Philip
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Sep 2015
- thioguanine / Generic mfg.
Trial completion, Minimal residual disease: S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 28, 2015
P2, N=79, Completed, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Sep 2015 Active, not recruiting --> Completed
- | Epratucyn (epratuzumab) / Gilead
Phase classification: Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Mar 26, 2015
P2, N=134, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Phase classification: P1/2 --> P2
- |||| Graspa (eryaspase) / PHAXIAM Therap
Enrollment open, Metastases: Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma (clinicaltrials.gov) - Mar 25, 2015
P2, N=90, Recruiting, Sponsor: ERYtech Pharma
Phase classification: P1/2 --> P2 Not yet recruiting --> Recruiting
- | Enrollment open, Trial initiation date: NEPAFOX: Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma (clinicaltrials.gov) - Mar 25, 2015
P2/3, N=126, Recruiting, Sponsor: Krankenhaus Nordwest
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Nov 2014
- | Enrollment closed, Metastases: FLOT4: 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer (clinicaltrials.gov) - Mar 25, 2015
P2/3, N=714, Active, not recruiting, Sponsor: Krankenhaus Nordwest
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- Vectibix (panitumumab) / Amgen, rilotumumab (AMG 102) / Amgen
Enrollment closed: MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma (clinicaltrials.gov) - Mar 24, 2015
P2, N=162, Active, not recruiting, Sponsor: UNICANCER
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly
Trial completion: A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver (clinicaltrials.gov) - Mar 24, 2015
P2, N=20, Completed, Sponsor: NSABP Foundation Inc
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, apitolisib (GDC-0980) / Roche
Enrollment change, Combination therapy, Metastases: GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 23, 2015
P1, N=43, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed N=33 --> 43
- |||||||||| Vectibix (panitumumab) / Amgen
New P3 trial: PARADIGM: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC (clinicaltrials.gov) - Mar 20, 2015
P3, N=800, Not yet recruiting, Sponsor: Takeda
- |||||||||| Vectibix (panitumumab) / Amgen
Biomarker, New P3 trial: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of MFOLFOX6 + Bevacizumab Versus MFOLFOX6 + Panitumumab Therapy in Patients with Chemotherapy-na (clinicaltrials.gov) - Mar 20, 2015
P3, N=800, Not yet recruiting, Sponsor: Takeda
- New P2 trial, New P3 trial: Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy (clinicaltrials.gov) - Mar 20, 2015
P2, N=50, Recruiting, Sponsor: Case Comprehensive Cancer Center
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment open: GCC 1314: Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma (clinicaltrials.gov) - Mar 17, 2015
P2, N=30, Recruiting, Sponsor: University of Maryland
N=33 --> 43 Not yet recruiting --> Recruiting
- | Enrollment open: COLOPEC: Adjuvant HIPEC in High Risk Colon Cancer (clinicaltrials.gov) - Mar 17, 2015
P3, N=176, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly
Enrollment closed: RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Sofia Perea, Director Clinical Trials Unit.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Biomarker, Enrollment closed, Combination therapy, Metastases: AC-ANGIOPREDICT: ANGIOPREDICT. ICORG 12-16, V3 (clinicaltrials.gov) - Mar 17, 2015
P2, N=224, Active, not recruiting, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment closed, Enrollment change: Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer (clinicaltrials.gov) - Mar 17, 2015
P1, N=13, Active, not recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=24 --> 13
- ||||||| Neulasta (pegfilgrastim) / Roche
Trial completion, Metastases: PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study (clinicaltrials.gov) - Mar 17, 2015
P3, N=847, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=24 --> 13 Active, not recruiting --> Completed
- Rituxan (rituximab) / Roche
Trial completion: Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=10, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| onartuzumab (RG3638) / Roche
Enrollment closed, Combination therapy, Metastases: A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer (clinicaltrials.gov) - Mar 16, 2015
P3, N=564, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting